ArticleClinical rheumatology2021

Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry.

Marco Sebastiani et al.PubMed ↗Publisher ↗

No numbers read from the abstract.